# Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

> **NCT05262517** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 126 (actual)

## Conditions studied

- Temporomandibular Disorders (TMD)

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05262517
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-05
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-05-18
- **Target enrollment:** 126 (ACTUAL)
- **Why stopped:** Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262517, "Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05262517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*